MBX Biosciences Inc (MBX)

Form 8-K - Current report

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage...

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

CARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8...

Form 144 - Report of proposed sale of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report